McKesson Corporation vs Micron Technology, Inc. — how do they compare? McKesson Corporation trades at $930.13 (market cap $108.46B), while Micron Technology, Inc. trades at $1,040.68 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 10.8× McKesson Corporation's market cap, and McKesson Corporation pays the higher dividend (0.4%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Micron Technology, Inc. for 48 Days on average.
| MCK | MU | |
|---|---|---|
Market Cap | $108.46B | $1.17T |
Volume | 712,607 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $995.69 | $1.21K |
52-Week Low | $725.17 | $181.60 |
Typical Hold Time | 74 Days | 48 Days |
Enterprise Value | $115.00B | $1.13T |
Dividend Yield | 0.4% | 0.06% |
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Micron Technology (MU) trades at $1,088, up 4.06% with strong bullish momentum, supported by consecutive earnings beats and robust AI-driven memory demand. The stock shows impressive fundamentals with 63.8% net margins and 91.77% ROE, while technical indicators signal bullish moving averages. Recent strategic customer agreements covering 35% of revenue through 2030 provide visibility, though growth deceleration concerns linger.
Outlook remains positive with analyst consensus at $1,590 price target (82.85% buy ratings), but risks include cyclical memory pricing, competitive pressures, and potential AI demand normalization. The stock's valuation appears reasonable with P/E of 13.94, supporting continued upside if execution persists.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →